Iran Press/ Europe: It also reduced the length of time patients spent in intensive care by between seven and 10 days, the UK health ministry said in a statement.
Most of the data came from when the drug was administered in addition to a corticosteroid, such as a dexamethasone, which has already been shown to improve patients’ chances of recovering from severe cases of COVID-19. The findings are awaiting peer review.
“This is a significant step forward for increasing survival of patients in intensive care with COVID-19,” the UK’s Deputy Chief Medical Officer Jonathan Van-Tam said in a statement.
The global death toll is 1,906,693 with 88,499,938 confirmed cases.
207/216
Read more:
WHO lists Pfizer/BioNTech vaccine for emergency use
5 science-backed ways to stop Covid-19 pandemic stress
